Home › Subarachnoid Hemorrhage › NCT06621329
Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
Who can join
Ages 18 to 100 · All sexes
Full eligibility criteria
Inclusion Criteria: * Acute subarachnoid hemorrhage * Age greater than 18 years * Secured aneurysm * Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision * maker * Patient or surrogate decision maker is available to consent Exclusion Criteria: * Less than 18 years old * Unsecured aneurysm * Pregnant or lactating * Prisoner * Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker * Nasal or facial trauma or surgery within the last three months * Allergy to lidocaine, bupivacaine, or dexamethasone * Patient is unable to consent and no available surrogate decision maker
About the study
The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.
What is being tested
- Transnasal sphenopalatine ganglion block (combination product)
Sponsor: University of California, Davis · Participants: 40 · Started: Oct 17, 2024
Contact the study team
- Janice Wang-Polagruto, PhD, CCRP · Phone: 916-551-3244
- Ryan Martin, MD · Phone: 916-734-4300
Official record on ClinicalTrials.gov — NCT06621329
Locations in the U.S.
| California | UC Davis Medical Center, Sacramento |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.